Together with the well-known pharmacogenetics effects on cancer risk and survival, we here reported a novel potential role of MTHFR and DHFR gene variants in determining and predicting the time of leukemia onset, adding new insights on the complex genetic and epigenetic mechanisms responsible for the wide postnatal latency of childhood leukemia. The gene discussed is MTHFR; the disease is cancer.